Tipranavir: a new protease inhibitor for the pediatric population

Expert Rev Anti Infect Ther. 2008 Dec;6(6):797-803. doi: 10.1586/14787210.6.6.797.


Highly active antiretroviral therapy can provide sustained viral suppression and a beneficial immunological response in both antiretroviral-naive and -experienced pediatric patients infected with HIV. While there have been many antiretroviral studies in adults infected with HIV, considerably less information is available in similar HIV-infected pediatric or adolescent patients. Tipranavir, a new-generation protease inhibitor approved for use in adults with resistant HIV strains, has recently been studied in HIV-infected children and adolescents. In this article, we summarize available pharmacokinetic, safety, tolerability and efficacy data obtained from children and adolescents treated with a pediatric tipranavir formulation.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / pharmacokinetics
  • Anti-HIV Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • HIV Infections / drug therapy*
  • Humans
  • Pyridines / adverse effects
  • Pyridines / pharmacokinetics
  • Pyridines / therapeutic use*
  • Pyrones / adverse effects
  • Pyrones / pharmacokinetics
  • Pyrones / therapeutic use*
  • Sulfonamides


  • Anti-HIV Agents
  • Pyridines
  • Pyrones
  • Sulfonamides
  • tipranavir